Nvidia vs. Infleqtion: Is the AI Giant or the Quantum Upstart the Better Buy Right Now?

The article argues Nvidia remains the better growth play, citing revenue and net income CAGRs of 45% and 69% from fiscal 2016 to 2026, with analysts expecting 39% revenue and EPS CAGR through fiscal 2029 and shares trading at 25x earnings. Infleqtion generated $32.5 million of revenue in 2025 and is expected to reach $69.4 million by 2028, but it trades at 37x 2028 sales and remains deeply unprofitable after its February SPAC debut. Overall tone is constructive on Nvidia and cautious on Infleqtion’s valuation.

Analysis

NVDA remains the cleaner expression of the AI capex cycle because it is still monetizing both breadth and urgency: hyperscalers are not just buying accelerators, they are buying time-to-deployment, and that keeps pricing power elevated even as inference architectures get more customized. The more important second-order effect is that NVDA’s ecosystem lock-in shifts bargaining power away from chip buyers and toward the software/networking stack, which should keep incremental share gains concentrated in a few infrastructure names rather than the broader semiconductor complex.

The market is likely underestimating how much of the next leg in AI spending will be a re-acceleration in networking, interconnect, memory, and power rather than just GPUs. That is positive for the supply chain, but it also raises the bar for AMD: even if its chips are competitive, it still lacks the same system-level control over software, routing, and deployment cadence, so its share gains are more likely to be episodic than structural over the next 6-12 months.

INFQ is a different kind of story: the business has real strategic utility, but the public-market framing is prematurely treating it like a scaled platform rather than a contract-dependent hardware vendor. The issue is not just valuation; it’s that government procurement can validate the technology while still failing to generate the volume and margin profile needed to justify a premium multiple, so any rerating probably requires a series of multi-year contract wins rather than one headline customer.

The contrarian view is that NVDA’s earnings multiple may look optically fine only because the market is capitalizing near-perfect execution. Any slowdown in hyperscaler capex, export constraints, or a faster-than-expected shift to lower-cost inference silicon would compress the multiple first and the growth rate second. By contrast, INFQ could outperform from here only if investors start paying for optionality on quantum-adjacent sensing, not for earnings power; that makes it a bad fundamental long but a potentially useful small-size venture-style exposure.

Key Decisions for Investors

• Stay long NVDA on any 3-5% pullback over the next 1-3 months; the risk/reward remains favorable as long as hyperscaler capex is intact, with downside mainly from multiple compression rather than thesis breakage.
• Avoid chasing INFQ outright; if we want quantum exposure, keep it as a small optionality basket position only, sized like a venture bet with a 12-24 month horizon and willingness to accept dilution risk.
• Pair trade: long NVDA / short AMD into the next 1-2 quarters; NVDA still has superior pricing power and ecosystem control, while AMD’s upside needs faster share gains than the market is likely to give credit for.
• Use call spreads rather than stock for NVDA if seeking convexity into the next earnings cycle; upside can continue, but the better trade is to define risk against valuation-driven pullbacks.
• Watch for a capex slowdown signal from hyperscalers over the next 90 days; that is the key catalyst that would warrant trimming NVDA and rotating into more defensive semicap names.